CN106237011A - A kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine - Google Patents

A kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine Download PDF

Info

Publication number
CN106237011A
CN106237011A CN201610646098.7A CN201610646098A CN106237011A CN 106237011 A CN106237011 A CN 106237011A CN 201610646098 A CN201610646098 A CN 201610646098A CN 106237011 A CN106237011 A CN 106237011A
Authority
CN
China
Prior art keywords
parts
group
blood circulation
membranous nephropathy
benefiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610646098.7A
Other languages
Chinese (zh)
Inventor
王世荣
邢建月
宋美卿
刘光珍
冯玛莉
贾力莉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanxi institute of traditional chinese medicine
Original Assignee
Shanxi institute of traditional chinese medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanxi institute of traditional chinese medicine filed Critical Shanxi institute of traditional chinese medicine
Priority to CN201610646098.7A priority Critical patent/CN106237011A/en
Publication of CN106237011A publication Critical patent/CN106237011A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the field of Chinese medicines, be specifically related to a kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein and disappear Chinese medicine.Erious adverse reaction present in prior art treatment membranous nephropathy, the inapparent problem of curative effect can be solved, be made up with method by a certain percentage of the Radix Astragali, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Semen Persicae, Flos Carthami, Pheretima part, Hirudo, Rhizoma Dioscoreae Nipponicae, Ramulus Euonymi and Fructus Crataegi.The present invention both can the immunologic function of enhancing body, the hypercoagulability of Patients With Kidney Diseases blood can be released again, repair and improve the filtration barrier of glomerule, thus reach to remove albuminuria, improve the purpose of renal function.

Description

A kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to a kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein and disappear Medicine.
Background technology
Membranous nephropathy (membranous nephropathy, MN): be the common cause of disease causing adult nephrotic syndrome One of, its course of disease repeatedly, chronic delay, be gradually reduced as main feature with High-grade Proteinuria and renal function clinically.Little with kidney Under ball visceral layer epithelial cell, immune complex diffusivity deposition, basement membrane thickened companion's nail are dashed forward and are formed as its pathological characteristics.Film Nephropathy can be divided into idiopathic membranous nephropathy (IMN) and Secondary cases membranous nephropathy according to the cause of disease.The cause of disease master of Secondary cases membranous nephropathy Drug therapy and the malignant tumor such as systemic lupus erythematosus (sle) to be had, virus infection, nonsteroidal anti-inflammatory.IMN is at kidney Modal a kind of histological type in sick syndrome, membranous nephropathy accounts for 2/3, account for primary glomerulopathy 9.9%～ 3.5%；The MN patient of 1/3 can be with spontaneous remission, and the adult patients of about 40% finally developed into end stagerenaldisease in 10 years. Albuminuria is MN main clinical manifestation, does not disappears.Albuminuria degree is relevant with the speed of renal function injury, and albuminuria is not only One mark of glomerular function obstacle, and primary disease can be relatively independent of cause Progressive symmetric erythrokeratodermia kidney substantial damage, accordingly, it is capable to make The Results that albuminuria reduces is advantageous for slowing down the progress of kidney disease.The pathogenesis of MN not yet illustrates.
The method of western medical treatment membranous nephropathy at present: using immunotherapy, single glucocorticoid is the most invalid；Sugar skin Matter hormons cell toxicity medicament (chlorambucil, cyclophosphamide, azathioprine) scheme is preferable, but untoward reaction is bigger；Promote The curative effects such as adrenocorticotropic hormone, mycophenolate, tacrolimus, anti-CD-20 monoclonal antibody, complement inhibitor very well but valency Lattice are expensive.
Although the most clinical and scientific research finds that therapy of combining Chinese and Western medicine MN determined curative effect, untoward reaction are little, but single Pure Chinese medicine IMN, curative effect is not significantly different from Western medicine, and can promote the plasma albumin of MN patient faster, Reducing albuminuria, increase hormone and hormone add the sensitivity of immunosuppressant invalid IMN patient treatment, and safety is high, bad React little, can take for a long time.
Knowable to the clinical observation and Experimental report of a lot of doctors, its deficiency of vital energy, blood stasis symptom are through each rank of nephropathy Section, the edema of nephropathy, albuminuria, hematuria, high-cholesterol disease, nitrogen matter delay etc., direct or indirect relation is all had with it.Old With the flat relation having analysed in depth kidney microcosmic pathology and Syndrome Differentiation of Traditional Chinese Medicine, according to it " empty, wet, the stasis of blood, heat " four of membranous nephropathy Big pathogenesis, " immune complex deposit filled the air under membranous nephropathy glomerular basement membrane epithelial cell surely belongs in theory of Chinese medical science wet in proposition Hot glue into the stasis of blood " understanding, with " benefiting QI for activating blood circulation eliminating dampness method " treat membranous nephropathy.Zhang Zhanping, Chen Hui etc. are to syndrome of deficiency of QI patient's Immunoglobulin and complement are measured analyzing, and contrast with normal healthy controls group, and result shows the body fluid of syndrome of deficiency of QI patient Immunologic function IgG, IgA, IgM, C3, C4 all have ascendant trend in various degree, and wherein IgG, IgM, C3, C4 compare with matched group Being statistically significant, the feature of the feature of this explanation IMN immunologic dysfunction and the immunologic dysfunction of syndrome of deficiency of QI has one Fixed concordance.Biochemical have the rising of metabolism disorder of blood lipid, platelet aggregation rate, blood plasma ratio with hemorheology aspect nephropathy stasis blocking card Viscosity, erythrocyte sedimentation rate, K value increase, have microthrombusis in glomerule, and mechanism is damp and hot resistance network, stagnation of blood stasis and heat, damp and hot high with blood Glutinous, high solidifying relevant.The drug combinations such as heat-clearing and toxic substances removing damp eliminating and blood circulation promoting and blood stasis dispelling can not only regulate the immunologic function of body, and can change Kind local blood circulation, suppresses and weakens allergy infringement.
Summary of the invention
The present invention is to solve erious adverse reaction present in prior art treatment membranous nephropathy, curative effect is inapparent asks Topic, it is provided that a kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine.
The present invention adopts the following technical scheme that realization:
A kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine, is made up of the raw material of following weight portion: the Radix Astragali 10-40 part, Radix Angelicae Sinensis 9-20 part, Rhizoma Chuanxiong 9-20 part, Semen Persicae 9-20 part, Flos Carthami 9-20 part, Pheretima 6-20 part, Hirudo 1-9 part, wear mountain Dragon 10-30 part, Ramulus Euonymi 10-30 part, Fructus Crataegi 10-30 part.
Each component optimum ratio scheme of the present invention is: the Radix Astragali 20 parts, Radix Angelicae Sinensis 12 parts, Rhizoma Chuanxiong 12 parts, 12 parts of Semen Persicae, 12 parts of Flos Carthami, Pheretima 10 parts, Hirudo 3 parts, Rhizoma Dioscoreae Nipponicae 15 parts, Ramulus Euonymi 15 parts, Fructus Crataegi 15 parts.
In the present invention, Radix Astragali slightly warm in nature；Sweet in the mouth；Return spleen, lung meridian；Benefit defends consolidating superficial resistance, tonifying Qi and lifting yang, promoting pus discharge and tissue regeneration strengthening, and diuretic disappears Swollen, anorexia and loose stool weak for the deficiency of vital energy, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, from juice night sweat, blood deficiency and yellow complexion, carbuncle of yin nature is unrestrained swollen, deficiency of vital energy water Swollen, interior-heat is quenched one's thirst.Radix Angelicae Sinensis is warm in nature, sweet in the mouth, pungent；Return liver, the heart, spleen channel；Promoting blood circulation and stopping pain, tonifying blood and regulating menstruation, loosening bowel to relieve constipation, for blood deficiency Dizziness, menoxenia, amenorrhea, dysmenorrhea, shallow complexion, traumatic injury, rheumatic arthralgia, ulcer sores, dryness of the intestine constipation.Rhizoma Chuanxiong Temperature；Acrid in the mouth；Return liver, gallbladder, heart channel；Blood-activating and qi-promoting, wind-expelling pain-stopping, for menoxenia, hypochondriac pain, the thoracic obstruction, skin infection swells and ache, and traumatic injury damages Wound, headache, rheumatic arthralgia.Semen Persicae is put down；Sweet in the mouth；Return lung, kidney, large intestine channel；The strong waist of tonifying the kidney to consolidate the essence, warming the lung Dingchuan, loosening bowel to relieve constipation, Breathing heavily for suffering from a deficiency of the kidney and cough, lumbago foot is soft, impotence and seminal emission, frequent micturition, stranguria caused by urinary stone, constipation due to dry stool.Flos Carthami is warm in nature；Acrid in the mouth；GUIXIN, liver Warp；Promoting blood circulation to restore menstrual flow, eliminating stasis to stop pain, for amenorrhea, dysmenorrhea, lochia, purplish or white patches on the skin abdominal mass mass in the abdomen, injury from falling down, skin infection swells and ache.Pheretima property Cold；Salty in the mouth；Return liver, spleen, bladder warp；Clearing away heat and relieving the wind syndrome, relievings asthma, dredging collateral, diuresis, and for high fever infantile convulsion, tetany, lung-heat is breathed heavily Cough, arthralgia, hemiplegia, accumulation of heat urine retention.Hirudo property is put down；Salty in the mouth, hardship；Return Liver Channel；Removing blood stasis is by silt, for amenorrhea, traumatic injury Damage.Rhizoma Dioscoreae Nipponicae is warm in nature；Sweet in the mouth, hardship；Return liver, kidney, lung meridian；Expelling wind and removing dampness, relaxes through dredging collateral, promoting blood circulation and stopping pain, relieving cough and asthma, is used for Rheumatic arthralgia, joint numbness, traumatic injury, lumbar sprain and QI divergeny, cough and asthma.Ramulus Euonymi is cold in nature；Bitter in the mouth；Return Liver Channel；Blood circulation promoting and blood stasis dispelling, Dredge the meridian passage.Fructus Crataegi is warm in nature；Sweet in the mouth, acid；Return liver, spleen, stomach warp；Promoting digestion and invigorating the stomach, blood circulation promoting and blood stasis dispelling, anthelmintic, for dyspepsia, Cardiovascular, cancer, enteritis, postpone menstrual period, curing postpartum bleeding.
In the present invention, the Radix Astragali is to reduce various kidney diseases to cause one of albuminuretic conventional Chinese medicine, proteinuria of renal disease patient Often there is the shortage of selenium, and selenium has the protection body function from oxidative damage, and some free radical scavenger can be strengthened Antioxidation, it is thus possible to by above-mentioned effect, electrostatic barrier and the mechanical barrier of protection glomerular basement membrane reduce albumen Urine, the Radix Astragali also has regulatory function to T lymphocyte；Pheretima can strengthen immunization, and earthworm decoction can reduce and oozes out, and shortens inflammation In the cycle, accelerate the healing of wound；The saliva of Hirudo has a kind of anticoagulative substance, referred to as hirudin, belong to 65 amino acid whose many Peptide, reuses hirudin and can reduce glomerule inner fibrin related antigen deposition, alleviate proliferation of glomerular mesangial cells and kidney Bead hardens, and alleviates albuminuria and hypoproteinemia, improves renal function；Radix Angelicae Sinensis has stronger anticoagulation and anti thrombotic action, its Blood coagulation resisting function mainly affects intrinsic coagulation system, and Radix Angelicae Sinensis can suppress the erythrocytic gathering that high molecular dextran causes Property strengthen, when give back to kidney ischemic reperfusion note damage there is protective effect；Ligustrazine by reduce immune complex deposit, Reduce urine protein filter, decrease microthrombusis in glomerule, expand blood vessel, protection kidney is played in the effect that improves Renal microcirculation Function；Ramulus Euonymi expansion blood vessel, increases renal blood flow, reduces the deposition of glomerule immune complex, promotes that protein closes Becoming, reduce urine protein, Rhizoma Dioscoreae Nipponicae all has significant inhibitory action to humoral and cellular immune response function.
The present invention reuses Radix Astragali QI invigorating；Close Radix Angelicae Sinensis, Radix Paeoniae Rubra, Rhizoma Chuanxiong, Pheretima, Semen Persicae, Flos Carthami Six-element blood circulation promoting and blood stasis dispelling in a small amount Medicine, it is not intended to invigorate blood circulation, and is the power dredging collateral invigorated blood circulation by means of it；Hirudo, Pheretima invigorate blood circulation disappear network lead to；And add Rhizoma Dioscoreae Nipponicae, ghost arrow Plumage blood circulation promoting and blood stasis dispelling diuretic；Add Fructus Crataegi both blood circulation promoting and blood stasis dispelling, the merit that blood fat reducingization of having again is stagnant.All medicines share, and play benefiting QI for activating blood circulation altogether, disappear Dredging collateral, fluent blood transports, and the stasis of blood goes the effect of network sum, both can the immunologic function of enhancing body, Patients With Kidney Diseases blood can be released again Hypercoagulability, repairs and improves the filtration barrier of glomerule, thus reach to remove albuminuria, improve the purpose of renal function.
The preparation method of Chinese medicine preparation of the present invention is: first by drug immersion 20-50min, every time with 2-4 times amount volume Soak by water 30-60min, continuous 1-3 time, stay liquid to remove slag, 80 DEG C are concentrated into the clear paste that relative density is 1.32-1.38；Decompression Dry, pulverize, sieve, mixing, it is prepared as conventional peroral dosage form, Co by conventional method60Sterilizing.
The effect of the present invention is described by zoopery.Tested rat: SD, SPF level, male, body weight (200 ± 20) g, Haidian, Beijing prosperity animal cultivation field provides, credit number: SCXK(capital) 2014-0013.Drugs compared is commercially available Radix Tripterygii Wilfordii Many glycosides sheet, lot number；150202, producer, ShangHai Fudan Fuhua Pharmaceutical Co., Ltd.
Experiment reagent: bovine albumin: lot number；20150319, producer, Chemical Reagent Co., Ltd., Sinopharm Group；
Carbonization diimmonium salt hydrochlorate (EDCHCL): lot number, 141201, producer, Shanghai Li Zhu east wind Bioisystech Co., Ltd；
Incomplete Freund's adjuvant (Frenund ' s Adjuvant, Incomplete): lot number, SLBL0210V, producer, the U.S. Sigma company；
Albumin reagent box (ALB, Bromocresol green): lot number, 20151015, producer, the safe clinical reagent of Beijing Northization is limited Company；
Carbamide mensuration test kit (Erea, urease-glutamate dehydrogenase enzyme process): lot number, 151212, producer, middle raw north control biology Science and Technology Co., Ltd.；
Creatinine time determine test kit (Cre, picric acid method): lot number, and 152851, producer, the limited public affairs of biotechnology share are controlled in middle raw north Department；
Anhydrous ethylenediamine (EDA), hydrochloric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate, acetic acid, anhydrous sodium acetate, wait reagent, be city Sell analytical pure.
Anti-ratCD3FITC (100 μ g), lot number 11-0030-82；Anti-ratCD8aPE (100 μ g), lot number 12- 0084-82；Anti-ratCD4PerCP-eFluor710 (100 μ g), lot number 46-0040-82, test kit is EBioscience company.
Experimental apparatus: double aobvious constant-temperature heating magnetic stirring apparatus: SH-3, Instrument Ltd. is opened up in Beijing North Cohan；
Freezer dryer: LGJ-18, Beijing Sihuan Scientific Instrument Factory Co., Ltd；
Full automatic closed dewaterer: Excelsior ES, Thermo company of the U.S.；
Paraffin wax embedding: TKY-BMB, the safe medical device corporations in Hubei；
Advanced retracting rotary microtome: F325, Thermo company of the U.S.；
Omnipotent fluoroscopic imaging systems: BX51-DP72, Japanese Olympus；
Transmission electron microscope: JEM-1011, Japan JEOL；
Automatic clinical chemistry analyzer: Chemray 360, Italian excellent despot；
Bag filter: MD77, molecular cut off, 8000-14000, Beijing Solarbio Science and Technology Ltd..
Experimental technique:
The first step, the preparation of cationization bSA (C-BSA): with reference to improvement Border method and preparation rat The documents and materials of heymann Nephritis Model, with 67ml anhydrous ethylenediamine (EDA) solution, are dissolved in the distilled water of 500 ml, then add Enter 6mol/L hydrochloric acid 350 ml, pH value is adjusted to 4.75, be subsequently cooled to 25 DEG C, be stirred, add natural Ox blood serum Albumin (N-BSA) 5 g is dissolved in 25 ml distilled water, adds 1.8 g carbonization diimmonium salt hydrochlorate (EDCHCL) again and continue after stirring Maintain the pH value of 25 DEG C and 4.75, continuous uniform stirring 2h, finally add 4mol/L (pH value 4.75) acetate buffer solution 30ml, terminate Reaction, obtains the C-BSA solution that isoelectric point, IP improves.C-BSA solution is placed in semi-transparent bag, with 4 DEG C of distilled waters dialysis 72h (3～ 5 h change water 1 time), after being dried to powder in vacuum lyophilization, i.e. prepare C-BSA dry powder, be stored in-80 DEG C of refrigerators standby With.Dissolve with 0.01mol/L pH7.4 PBS before injection and be configured to solution.
Second step, model immunization: with reference to Border method: modeling group rat uses C-BSA lmg the completeest with equivalent Freund After full adjuvant mixing, make the method for subcutaneous multi-point injection at the groin of rat and bilateral oxter and carry out pre-immunity, the next day 1 Secondary, carry out formal immunity after 1 week, every rat C-BSA 16 mg/Kg(is dissolved in the PBS that 1 ml pH value is 7.4) tail vein Injection, the next day 1 time, 3 times a week, continuous 4 weeks, normal group did not processed.
3rd step, animal packet and administration: take SD rat, it is divided into blank, model group, positive group (Radix Tripterygii Wilfordii), basis Invent low (people's consumption per day 7.5 times), in (people's consumption per day 15 times), high dose (people's consumption per day 30 times) totally 6 groups, except blank and Outside model group gavage distilled water, after remaining group modeling, gavage gives relative medicine, once a day, successive administration 4 weeks, gavage volume 10ml/kg。
4th step, Indexs measure:
(1) urine protein detection, before and after drug treatment the 4th of i.e. formal immunity the, 8 weekends, collects 2 24h urine by rat metabolism cage Liquid, uses picric acid method, measures 24h urine protein quantitation,
(2) renal function detection, drug treatment the 4th weekend, with 10% chloral hydrate (3.5ml/1kg) anesthetized rat, postcava takes Blood, stands 30min, 2500r/min centrifuging and taking supernatant rat blood serum, put-20 DEG C standby, use kit measurement renal function: carbamide Nitrogen, creatinine.
(3) T cell subsets counts, after rat oral gavage is administered, uses chloral hydrate 10% (3.5/kg) intraperitoneal injection of anesthesia, Postcava takes blood about 1 ml, is placed in EDTA-K2 anticoagulant tube, takes blood 100 μ l, adds the CD3 of little anti-rat respectively+-FITC、 CD4+PerCP、CD8+-PE fluorescently-labeled monoclonal antibody 20 μ l is in test tube, and labelling, room temperature is placed after 15min, added haemolysis Element 500 μ l, room temperature lucifuge 15 min, be that 500 r/min are centrifuged 5min with rotating speed, remove supernatant, add 500 μ l PBS liquid, gently Concussion 10min, uses flow cytomery CD3 immediately+、CD4+、CD8+、CD4+/CD8+Percentage ratio (%).
(4) Pathological histological observation (optical microscope)
Putting to death rat and leave and take part nephridial tissue, the paraformaldehyde solution of 10% is fixed, and ethanol gradient is dehydrated step by step, paraffin embedding system Becoming the section of 2 μm, row HE, PAS, Masson dye, and observe glomerule and the situation of change of renal interstitial, and Taking Pictures recording.
(5) observation (ultramicroscope) of ultrastructure in kidney
Rinsing 3 times with 0.1M phosphoric acid rinsing liquid, 1% osmic acid fixative is fixed, then rinses 3 times with 0.1M phosphoric acid rinsing liquid；Conventional de- Water, embed, solidify, ultramicrotome section, the double dyeing of 3% acetic acid uranium-lead citrate, transmission electron microscope observing, film making.
Accompanying drawing explanation
Fig. 1 is the impact of blank group Membranous Nephritis Rats renal tissue morphology HE dyeing under different multiplying；
Fig. 2 is the impact of different multiplying drag matched group Membranous Nephritis Rats renal tissue morphology HE dyeing；
Fig. 3 is the impact that under different multiplying, Membranous Nephritis Rats renal tissue morphology HE is dyeed by Glucosidorum Tripterygll Totorum group；
Fig. 4 is the shadow that under different multiplying, Membranous Nephritis Rats renal tissue morphology HE is dyeed by powder low dose group of the present invention Ring；
Fig. 5 is the shadow that under different multiplying, in powder of the present invention, Membranous Nephritis Rats renal tissue morphology HE is dyeed by dosage group Ring；
Fig. 6 is the shadow that under different multiplying, Membranous Nephritis Rats renal tissue morphology HE is dyeed by powder high dose group of the present invention Ring；
Fig. 7 is the impact of blank group Membranous Nephritis Rats renal tissue morphology PAS dyeing under different multiplying；
Fig. 8 is the impact of different multiplying drag matched group Membranous Nephritis Rats renal tissue morphology PAS dyeing；
Fig. 9 is the impact that under different multiplying, Membranous Nephritis Rats renal tissue morphology PAS is dyeed by Glucosidorum Tripterygll Totorum group；
Figure 10 is the shadow that under different multiplying, Membranous Nephritis Rats renal tissue morphology PAS is dyeed by powder low dose group of the present invention Ring；
Figure 11 is the shadow that under different multiplying, in powder of the present invention, Membranous Nephritis Rats renal tissue morphology PAS is dyeed by dosage group Ring；
Figure 12 is the shadow that under different multiplying, Membranous Nephritis Rats renal tissue morphology PAS is dyeed by powder high dose group of the present invention Ring；
Figure 13 is the impact of blank group Membranous Nephritis Rats renal tissue morphology Masson dyeing under different multiplying；
Figure 14 is the impact of different multiplying drag matched group Membranous Nephritis Rats renal tissue morphology Masson dyeing；
Figure 15 is the shadow that under different multiplying, Membranous Nephritis Rats renal tissue morphology Masson is dyeed by Glucosidorum Tripterygll Totorum group Ring；
Figure 16 is that under different multiplying, Membranous Nephritis Rats renal tissue morphology Masson is dyeed by powder low dose group of the present invention Impact；
Figure 17 is that under different multiplying, in powder of the present invention, Membranous Nephritis Rats renal tissue morphology Masson is dyeed by dosage group Impact；
Figure 18 is that under different multiplying, Membranous Nephritis Rats renal tissue morphology Masson is dyeed by powder high dose group of the present invention Impact；
Figure 19 is the impact of blank group Membranous Nephritis Rats ultrastructure in kidney change under different multiplying；
Figure 20 is the impact of different multiplying drag matched group Membranous Nephritis Rats ultrastructure in kidney change；
Figure 21 is the impact that under different multiplying, Membranous Nephritis Rats ultrastructure in kidney is changed by Glucosidorum Tripterygll Totorum group；
Figure 22 is the impact that under different multiplying, Membranous Nephritis Rats ultrastructure in kidney is changed by powder low dose group of the present invention；
Figure 23 is the impact that under different multiplying, in powder of the present invention, Membranous Nephritis Rats ultrastructure in kidney is changed by dosage group；
Figure 24 is the impact that under different multiplying, Membranous Nephritis Rats ultrastructure in kidney is changed by powder high dose group of the present invention.
Detailed description of the invention
Embodiment 1
A kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine, is made up of the raw material of following weight proportion: yellow Stilbene 20 grams, Radix Angelicae Sinensis 12 grams, Rhizoma Chuanxiong 12 grams, 12 grams of Semen Persicae, 12 grams of Flos Carthami, Pheretima 10 grams, Hirudo 3 grams, Rhizoma Dioscoreae Nipponicae 15 grams, Ramulus Euonymi 15 grams, Fructus Crataegi 15 grams.First by drug immersion 30min, every time with the soak by water 40min of 3 times amount volumes, continuous 2 times, liquid is stayed to go Slag, 80 DEG C are concentrated into the clear paste that relative density is 1.32-1.38；Drying under reduced pressure, pulverizes, sieves, and mixing is prepared in conventional manner Become powder, Co60Sterilizing.
Embodiment 2
A kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine, is made up of the raw material of following weight proportion: yellow Stilbene 10 grams, Radix Angelicae Sinensis 9 grams, Rhizoma Chuanxiong 9 grams, 9 grams of Semen Persicae, 9 grams of Flos Carthami, Pheretima 6 grams, Hirudo 1 gram, Rhizoma Dioscoreae Nipponicae 10 grams, Ramulus Euonymi 10 grams, Fructus Crataegi 10 grams.First by drug immersion 20min, every time with the soak by water 30min of 2 times amount, 1 time, staying liquid to remove slag, 80 DEG C are concentrated into Relative density is the clear paste of 1.32-1.38；Drying under reduced pressure, pulverizes, sieves, and mixing is prepared as capsule, Co in conventional manner60Go out Bacterium.
Embodiment 3
A kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine, is made up of the raw material of following weight proportion: yellow Stilbene 40 grams, Radix Angelicae Sinensis 20 grams, Rhizoma Chuanxiong 20 grams, 20 grams of Semen Persicae, 20 grams of Flos Carthami, Pheretima 20 grams, Hirudo 9 grams, Rhizoma Dioscoreae Nipponicae 30 grams, Ramulus Euonymi 30 grams, Fructus Crataegi 30 grams.First by drug immersion 50min, every time with the soak by water 60min of 4 times amount, continuous 3 times, liquid is stayed to remove slag, 80 DEG C are concentrated into the clear paste that relative density is 1.32-1.38；Drying under reduced pressure, pulverizes, sieves, and mixing is prepared as in conventional manner Tablet, Co60Sterilizing.
Experimental example, illustrates the effect of the present invention below by way of zoopery, and in experiment, Chinese medicine preparation used is embodiment 1 Described Chinese medicine preparation.Drugs compared is commercially available Glucosidorum Tripterygll Totorum.
(1) powder of the present invention is on Membranous Nephritis Rats urine protein and the impact of renal function
Result shows: after modeling each group of 24h urine protein quantitation be all remarkably higher than blank group (p＜ 0.05,p＜ 0.01)；Give Model control group 24h urine protein quantitation after medicine, BUN, CR be all remarkably higher than Normal group (p＜ 0.01,p＜ 0.05,p＜ 0.001), Tripterygium glycosides and powder of the present invention middle and high dosage group 24h urine protein quantitation significantly lower than model group (p＜ 0.001), Tripterygium glycosides and powder high dose group BUN of the present invention significantly lower than model group (p＜ 0.05,p＜ 0.01), Thunder God The many glycosides of rattan and powder of the present invention basic, normal, high dosage group CR significantly lower than model group (p＜ 0.001)；Show, model success, this Bright powder has reduction albuminuria and the effect of blood BUN, CR, is shown in Table 1.
Table 1 powder of the present invention on the impact of Membranous Nephritis Rats 24h urine protein quantitation and serum BUN, CR (meansigma methods ±s)
Compare with model control group:* P<0.05,* P<0.01, * * P<0.001；
Compare with blank group:▲ P<0.05,▲▲ P<0.01
(2) the powder of the present invention impact on Membranous Nephritis Rats lymphocyte populations
Result shows: model control group CD3+、CD4+、CD8+All be substantially less than blank group (P< 0.001,P< 0.001,P< 0.01)；Tripterygium glycosides group CD3+、CD4+、CD8+Percentage rate, powder of the present invention dosage CD3 low, middle+、CD4+, high dose CD3+、CD4+、CD8+Percentage rate be all remarkably higher than model control group (P< 0.01,P< 0.001,P< 0.01,P< 0.05,P< 0.001,P < 0.01,P< 0.01,P< 0.01).Show Membranous Nephritis Rats immune system t lymphocyte subset group (CD3+、CD4+、CD8+) water Flat low, and powder of the present invention is to t lymphocyte subset group (CD3+、CD4+、CD8+) level has and increase effect, is shown in Table 2.
Table 2 powder of the present invention on the impact of Membranous Nephritis Rats T lymphocyte populations (meansigma methods ±s)
Group Number of cases CD3+(%) CD4+(%) CD8+(%) CD4+/CD8+
Blank group 12 60.2±14.12*** 33.1±5.59*** 18.8±7.80** 2.12±1.02
Model control group 12 37.8±6.57 18.3±4.01 10.9±4.46 2.02±1.18
Radix Tripterygii Wilfordii 12 50.3±8.74** 26.5±6.47*** 17.6±6.43** 1.77±.95
Powder low dosage of the present invention 10 53.3±4.96*** 33.0±3.82*** 13.9±3.09 2.51±.75
Middle dosage 10 47.9±5.51* 28.1±3.22*** 11.9±2.45 2.48±.66
High dose 10 52.4±11.02** 26.1±6.78** 19.3±6.76** 1.57±.94
Compare with model control group:* P<0.05,* P<0.01, * * P<0.001；
(3) powder of the present invention impact morphologic on Membranous Nephritis Rats renal tissue
The histological change of Pathological (optical microscope)
As shown in Fig. 1 to Figure 18, each group rat kidney, through embedding fixing, conventional, film-making, is observed after HE, PAS, MASSON dyeing, Result is shown: in addition to normal group, and remaining is respectively organized glomerular volume and slightly increases, and blood capillary tube chamber all has in various degree narrow or closes Plug, GCBM diffusivity is uneven substantially to be thickened, stiff, and renal cells is in filling the air or focal Cavity and or granular degeneration, visible protein cast in part tubule, PAS, MASSON dyeing can substantially see glomerular mesangium district and Basement membrane thickened, it is seen that nail is prominent to be formed, and model group is the most obvious, administration group all has compared with model group and the most significantly changes Kind effect.
The change (ultramicroscope) of ultrastructure in kidney
As shown in Figure 19 to Figure 24, blank group: multiple blood capillaries (Cap) seen from Electronic Speculum, intracavity has erythrocyte (Er)； Blood vessel has endotheliocyte (Ed), is evenly distributed, without swelling, the podocytic process (F) separated with podocyte (Poc) outward, podocytic process Clear amixis；Thin away from the kytoplasm at nucleus and have micro-fenestra；Being basement membrane (BM) outside endotheliocyte, complete clear thickness is equal Even, deposit without electron-dense thing, 3-tier architecture is clear；Mesangial cell (MC) is positioned in the mesangial region of adjacent blood capillary, without expanding Greatly, have no that proliferation of mesangial cells substrate increases.
Model control group: visible blood capillary under Electronic Speculum, intracavity has a large amount of erythrocyte stasis of blood to amass；Endotheliocytic swelling, cavity Degeneration, its micro-fenestra disappears or smudgy；The podocytic process of podocyte extensively merges the most even podocytic process and disappears, and has the most false floss Galley proof changes；Basement membrane compared with normal group thickens, it is seen that electron-dense thing deposits；Mesangial region is broadening, mesangial cell and extracellular matrix Slight hypertrophy.
Administration group: under Glucosidorum Tripterygll Totorum, administration high and low dose group Electronic Speculum, visible blood capillary intracavity blood stasis situation is obvious Improve；Endothelial cell morphology is significantly better than model group, it is seen that micro-fenestra, but endotheliocyte podocytic process merges and pseudovilli sample changes bright Showing and alleviate, partially visible podocytic process recovers normally or close to normal condition；Basement membrane thickened alleviates almost without electron-dense thing deposition； Mesangial region still has slight broadening phenomenon；Each administration group glomerulus ultrastructure the most relatively model group has improvement, and is administered high and low dose Some is close normal for group structure.

Claims (2)

1. a benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine, it is characterised in that: by following weight portion Raw material form: Radix Astragali 10-40 part, Radix Angelicae Sinensis 9-20 part, Rhizoma Chuanxiong 9-20 part, Semen Persicae 9-20 part, Flos Carthami 9-20 part, Pheretima 6-20 part, Hirudo 1-9 part, Rhizoma Dioscoreae Nipponicae 10-30 part, Ramulus Euonymi 10-30 part, Fructus Crataegi 10-30 part.
2. according to a kind of shown in claim 1, there is the benefiting QI for activating blood circulation for the treatment of membranous nephropathy urine protein to disappear Chinese medicine, its feature It is: be made up of the raw material of following weight portion: the Radix Astragali 20 parts, Radix Angelicae Sinensis 12 parts, Rhizoma Chuanxiong 12 parts, 12 parts of Semen Persicae, 12 parts of Flos Carthami, Pheretima 10 parts, Hirudo 3 parts, Rhizoma Dioscoreae Nipponicae 15 parts, Ramulus Euonymi 15 parts, Fructus Crataegi 15 parts.
CN201610646098.7A 2016-08-09 2016-08-09 A kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine Pending CN106237011A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610646098.7A CN106237011A (en) 2016-08-09 2016-08-09 A kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610646098.7A CN106237011A (en) 2016-08-09 2016-08-09 A kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine

Publications (1)

Publication Number Publication Date
CN106237011A true CN106237011A (en) 2016-12-21

Family

ID=58077800

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610646098.7A Pending CN106237011A (en) 2016-08-09 2016-08-09 A kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine

Country Status (1)

Country Link
CN (1) CN106237011A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270870A (en) * 2023-03-21 2023-06-23 天津中医药大学第一附属医院 Traditional Chinese medicine composition for treating membranous nephropathy and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270870A (en) * 2023-03-21 2023-06-23 天津中医药大学第一附属医院 Traditional Chinese medicine composition for treating membranous nephropathy and preparation method thereof
CN116270870B (en) * 2023-03-21 2024-02-02 天津中医药大学第一附属医院 Traditional Chinese medicine composition for treating membranous nephropathy and preparation method thereof

Similar Documents

Publication Publication Date Title
MXPA03003446A (en) Novel medicinal herbal composition for treating liver diseases and hiv.
CN102423478B (en) Pharmaceutical composition for treating chronic endometritis
US10413582B2 (en) Pharmaceutical composition for treating eczema and method for preparation thereof
CN105853678A (en) Traditional Chinese medicinal composition for treating membranous nephropathy and method for preparing traditional Chinese medicinal composition for treating membranous nephropathy
CN105056128B (en) A kind of Chinese medicine composition and preparation method and application for treating atrophic gastritis and intestines
CN106237011A (en) A kind of benefiting QI for activating blood circulation with treatment membranous nephropathy urine protein disappears Chinese medicine
CN104042895A (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof
CN103705731B (en) A kind of Chinese medicine composition for the treatment of chronic alcoholic toxic liver disease
CN103948754B (en) Drug for treating renal-deficiency humid-heat type chronic nephritis
CN104095904A (en) Medical composition for treating bile related diseases, and preparation method and application thereof
CN103386104B (en) Traditional Chinese medicine composite for curing erysipelas and preparation method thereof
CN105477246A (en) Traditional Chinese medicine composition for treating phlegmatic hygrosis type mammary gland hyperplasia and preparation method thereof
CN102688469B (en) Traditional Chinese medicine extract and preparation method and application thereof
CN105326982A (en) Traditional Chinese medicine preparation for treating plasma cell mastitis and preparation method thereof
CN105125804A (en) Traditional Chinese medicine preparation for treating cirrhosis ascites and preparation method of traditional Chinese medicine preparation
CN105412397A (en) Traditional Chinese medicine for treating chronic pyothorax and preparation method of traditional Chinese medicine
CN104523974A (en) Traditional Chinese medicine preparation for preventing and treating hepatic fibrosis, soft capsule for preventing and treating hepatic fibrosis and preparing process of traditional Chinese medicine preparation and soft capsule
CN116531476A (en) Traditional Chinese medicine composition for treating spasmolytic polypeptide expression metaplasia and application thereof
CN110721290A (en) A topical powder or paste for treating gynecological diseases, and its preparation method
CN117281883A (en) Traditional Chinese medicine composition for preventing and treating obesity-related chronic pancreatitis
CN100486629C (en) Psoriasis treating Chinese medicine preparation
CN101293037B (en) Segmented intestine targeting medicine delivery preparation of Chinese medicine and preparation method thereof
CN114146158A (en) Coptis decoction composition, coptis decoction extract and preparation method and application thereof
CN118286371A (en) Fatty liver prevention and treatment medicine and preparation method thereof
NZ737773A (en) Pharmaceutical composition for treating eczema and method for preparation thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20161221

RJ01 Rejection of invention patent application after publication